The New York-based drugmaker reported GAAP earnings of $848 million, or 43 cents a share, vs. $338 million, or 17 cents a share, in the year-ago quarter.
Before items, the company earned $764 million, or 38 cents a share, up from $438 million, or 22 cents a share, in the 2006 period. Analysts surveyed by Thomson Financial had expected 37 cents a share on revenue of $5.02 billion.
Bristol said net sales increased 22% to $5.1 billion. The company said the increase reflects growth in key and newer products and the adverse impact of generic drug competition that hurt sales in the comparable 2006 quarter.Sales of Plavix increased 99% to $1.25 billion and rose 128% in the U.S. Sales in the year-ago quarter suffered from generic competition. Another sizable sales increase came from the company's Abilify for schizophrenia, acute bipolar mania and bipolar disorder, which rose 34% to $420 million. International sales increased 72% (including a 12% favorable foreign exchange impact) to $91 million. Bristol's revenue for Abilify consists of alliance revenue representing its 65% share of net sales in countries where it copromotes the drug with Otsuka Pharmaceutical.